Full-Life wants to carry actinium-225 directly to c-MET tumors. Can FL-261 widen targeted alpha therapy beyond prostate cancer?
FDA clears Full-Life’s actinium-225 FL-261 for Phase 1 testing in c-MET-positive lung cancer as the radiopharmaceutical company expands its pipeline.